NASDAQ:GNCA Genocea Biosciences (GNCA) Stock Forecast, Price & News $0.0002 0.00 (0.00%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$0.0002▼$0.000250-Day Range N/A52-Week Range$0.0001▼$0.0001Volume645 shsAverage Volume83,499 shsMarket Capitalization$11,746.00P/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Genocea Biosciences (NASDAQ:GNCA) StockGenocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.Read More GNCA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNCA Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comGenocea Biosciences (NASDAQ:GNCA) Coverage Initiated by Analysts at StockNews.comJanuary 27, 2023 | seekingalpha.comGNCAQ Genocea Biosciences, Inc.September 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsAugust 31, 2022 | thestreet.com3 Health Care Stocks Under $10 to Trade for BreakoutsAugust 9, 2022 | uk.finance.yahoo.comGenocea Biosciences, Inc. (GNCA)May 27, 2022 | seekingalpha.comGRPN, GNCA and LAB among mid-day moversMay 25, 2022 | finance.yahoo.comGenocea Biosciences to shut downMay 24, 2022 | finance.yahoo.comGenocea Closes Shop, Delists From NASDAQSeptember 28, 2023 | Micro-Cap Stock Trader (Ad)U.S. drive to onshore battery supply chains could create big winners in lithiumInvestor Find Lithium Gold and Crush the Bear Market with 32k Metric TonsMay 24, 2022 | finance.yahoo.comThree weeks after layoffs, Genocea shuts down entirelyMay 24, 2022 | seekingalpha.comGenocea stock crashes 64% on winding down of operations, Nasdaq delistingMay 24, 2022 | finance.yahoo.comGenocea Announces Wind Down of Operations and Delisting From NASDAQMay 2, 2022 | finance.yahoo.comGenocea cuts two-thirds of staff, explores a saleApril 29, 2022 | seekingalpha.comGenocea stock plunges on cutting workforce by 65% and exploring sale or merger alternatives; Stifel cuts PT to $0.16April 28, 2022 | finance.yahoo.comGenocea Initiates Restructuring and Announces Plan to Explore Strategic AlternativesApril 11, 2022 | finance.yahoo.comImplied Volatility Surging for Genocea (GNCA) Stock OptionsApril 8, 2022 | uk.investing.comGenocea Biosciences Stock Dives After Early Data From GEN-011 Trial In Pretreated Solid Tumor PatientsApril 8, 2022 | finance.yahoo.comGenocea Presents Encouraging Initial Data from GEN-011 Phase 1/2a Trial at AACR 2022April 4, 2022 | finance.yahoo.comGenocea Biosciences to Host Investor WebinarMarch 14, 2022 | finance.yahoo.comGenocea to Present at the 32nd Annual Oppenheimer Healthcare ConferenceMarch 10, 2022 | seekingalpha.comGenocea Biosciences GAAP EPS of -$0.19 misses by $0.01March 10, 2022 | apnews.comGenocea Biosciences: Q4 Earnings SnapshotMarch 10, 2022 | finance.yahoo.comGenocea Provides Fourth Quarter 2021 Corporate UpdateMarch 9, 2022 | seekingalpha.comGenocea Biosciences Q4 2021 Earnings PreviewMarch 9, 2022 | benzinga.comGenocea Biosciences Earnings PreviewMarch 8, 2022 | finance.yahoo.comGenocea to Present Clinical and Preclinical Data at AACR Annual MeetingMarch 3, 2022 | finance.yahoo.comGenocea to Host Fourth Quarter 2021 Corporate Update Conference Call & WebcastSee More Headlines Receive GNCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genocea Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GNCA Company Calendar Last Earnings10/27/2021Today9/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GNCA CUSIPN/A CIK1457612 Webwww.genocea.com Phone(617) 876-8191Fax617-876-8192Employees74Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-33,200,000.00 Net MarginsN/A Pretax Margin-1,946.15% Return on Equity-182.88% Return on Assets-62.76% Debt Debt-to-Equity Ratio0.24 Current Ratio1.35 Quick Ratio1.35 Sales & Book Value Annual Sales$1.91 million Price / Sales0.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book0.00Miscellaneous Outstanding Shares58,730,000Free Float57,788,000Market Cap$11,746.00 OptionableOptionable Beta1.61 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. William D. Clark M.B.A. (Age 53)Pres, CEO & Director Comp: $837.42kDr. Jessica Baker Flechtner Ph.D. (Age 50)Chief Scientific Officer Comp: $585.18kMs. Diantha Duvall CPA (Age 50)M.B.A., CFO & Sec. Key CompetitorsAllena PharmaceuticalsNASDAQ:ALNAQGenocea BiosciencesNASDAQ:GNCAQPhaseBio PharmaceuticalsNASDAQ:PHASStatera BiopharmaNASDAQ:STABViveve MedicalNASDAQ:VIVEView All Competitors GNCA Stock - Frequently Asked Questions How have GNCA shares performed in 2023? Genocea Biosciences' stock was trading at $0.0002 at the start of the year. Since then, GNCA shares have increased by 0.0% and is now trading at $0.0002. View the best growth stocks for 2023 here. How were Genocea Biosciences' earnings last quarter? Genocea Biosciences, Inc. (NASDAQ:GNCA) posted its quarterly earnings results on Wednesday, October, 27th. The biotechnology company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.15. The biotechnology company had revenue of $1.64 million for the quarter. During the same quarter in the previous year, the firm posted ($0.26) EPS. What is William Clark's approval rating as Genocea Biosciences' CEO? 5 employees have rated Genocea Biosciences Chief Executive Officer William Clark on Glassdoor.com. William Clark has an approval rating of 82% among the company's employees. What other stocks do shareholders of Genocea Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genocea Biosciences investors own include Hawkins (HWKN), CA (CA), Endologix (ELGX), Chipotle Mexican Grill (CMG), BlackRock (BLK), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Hudson Technologies (HDSN), Accenture (ACN) and AutoZone (AZO). What is Genocea Biosciences' stock symbol? Genocea Biosciences trades on the NASDAQ under the ticker symbol "GNCA." How do I buy shares of Genocea Biosciences? Shares of GNCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genocea Biosciences' stock price today? One share of GNCA stock can currently be purchased for approximately $0.00. How much money does Genocea Biosciences make? Genocea Biosciences (NASDAQ:GNCA) has a market capitalization of $11,746.00 and generates $1.91 million in revenue each year. The biotechnology company earns $-33,200,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis. How can I contact Genocea Biosciences? Genocea Biosciences' mailing address is 100 ACORN PARK DRIVE, CAMBRIDGE MA, 02140. The official website for the company is www.genocea.com. The biotechnology company can be reached via phone at (617) 876-8191, via email at ir@genocea.com, or via fax at 617-876-8192. This page (NASDAQ:GNCA) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genocea Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.